Search Results - "Lyon, R A"

Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device – the SERCA-LVAD TRIAL by Lyon, A. R., Babalis, D., Morley-Smith, A. C., Hedger, M., Suarez Barrientos, A., Foldes, G., Couch, L. S., Chowdhury, R. A., Tzortzis, K. N., Peters, N. S., Rog-Zielinska, E. A., Yang, H-Y, Welch, S., Bowles, C. T., Rahman Haley, S., Bell, A. R., Rice, A., Sasikaran, T., Johnson, N. A., Falaschetti, E., Parameshwar, J., Lewis, C., Tsui, S., Simon, A., Pepper, J., Rudy, J. J., Zsebo, K. M., Macleod, K. T., Terracciano, C. M., Hajjar, R. J., Banner, N., Harding, S. E.

“…The SERCA-LVAD trial was a phase 2a trial assessing the safety and feasibility of delivering an adeno-associated vector 1 carrying the cardiac isoform of the…”
Get full text

In vitro pharmacology of ambroxol: Potential serotonergic sites of action by Hull, J.D., Lyon, R.A.

“…Ambroxol is a muco-active agent with multiple, clinically relevant effects in the airway. Despite its widespread use and well documented clinical efficacy,…”
Get full text

The prevalence of iron deficiency and anemia and their impact on survival in patients at a cardio-oncology clinic by Čiburienė, E., Čelutkienė, J., Aidietienė, S., Ščerbickaitė, G., Lyon, A. R.

“…Abstract Background Iron deficiency (ID) and anemia are common in both heart failure (HF) and cancer patients and are associated with poor quality of life and…”
Get full text

Gene therapy: targeting the myocardium by Lyon, A R, Sato, M, Hajjar, R J, Samulski, R J, Harding, S E

“…Effective clinical delivery of gene therapy to the heart requires understanding and design of complex biological systems to deliver therapeutic gene…”
Get more information

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up by Haanen, J., Obeid, M., Spain, L., Carbonnel, F., Wang, Y., Robert, C., Lyon, A.R., Wick, W., Kostine, M., Peters, S., Jordan, K., Larkin, J.

“…•This ESMO Clinical Practice Guideline provides key recommendations for managing immunotherapy-related toxicity.•The guideline covers assessment, diagnosis and…”
Get full text

Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations by Curigliano, G., Lenihan, D., Fradley, M., Ganatra, S., Barac, A., Blaes, A., Herrmann, J., Porter, C., Lyon, A.R., Lancellotti, P., Patel, A., DeCara, J., Mitchell, J., Harrison, E., Moslehi, J., Witteles, R., Calabro, M.G., Orecchia, R., de Azambuja, E., Zamorano, J.L., Krone, R., Iakobishvili, Z., Carver, J., Armenian, S., Ky, B., Cardinale, D., Cipolla, C.M., Dent, S., Jordan, K.

“…Cancer and cardiovascular (CV) disease are the most prevalent diseases in the developed world. Evidence increasingly shows that these conditions are…”
Get full text

Cardiotoxicity Following Cancer Treatment by Walls, G M, Lyon, A R, Harbinson, M T, Hanna, G G

“…More than half of those born after 1960 will develop cancer during their lifetime. Fortunately, owing to improved diagnosis and treatment, cure rates have…”
Get full text

What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist? by Andres, M.S., Pan, J., Lyon, A.R.

“…Cardio-oncology is an emerging subspecialty arising from the need for multidisciplinary collaboration to address the increasing prominence of cardiovascular…”
Get full text

Myocardial MiR-30 downregulation triggered by doxorubicin drives alterations in β-adrenergic signaling and enhances apoptosis by Roca-Alonso, L, Castellano, L, Mills, A, Dabrowska, A F, Sikkel, M B, Pellegrino, L, Jacob, J, Frampton, A E, Krell, J, Coombes, R C, Harding, S E, Lyon, A R, Stebbing, J

“…The use of anthracyclines such as doxorubicin (DOX) has improved outcome in cancer patients, yet associated risks of cardiomyopathy have limited their clinical…”
Get full text

Expert Consensus on the Management of Adverse Events During Treatment with Lenvatinib for Thyroid Cancer by Reed, N., Glen, H., Gerrard, G., Good, J., Lei, M., Lyon, A.R., Strachan, M., Wadsley, J., Newbold, K.

“…Lenvatinib is an oral multi-kinase inhibitor approved for the treatment of adults with progressive, locally advanced or metastatic, differentiated thyroid…”
Get full text

Physiological, pharmacological and toxicological considerations of drug‐induced structural cardiac injury by Cross, M J, Berridge, B R, Clements, P J M, Cove‐Smith, L, Force, T L, Hoffmann, P, Holbrook, M, Lyon, A R, Mellor, H R, Norris, A A, Pirmohamed, M, Tugwood, J D, Sidaway, J E, Park, B K

“…The incidence of drug‐induced structural cardiotoxicity, which may lead to heart failure, has been recognized in association with the use of anthracycline…”
Get full text

Myocardial tissue engineering: a review by Jawad, H., Ali, N. N., Lyon, A.R., Chen, Q. Z., Harding, S. E., Boccaccini, A. R.

“…Myocardial tissue engineering, a concept that intends to overcome the obstacles to prolonging patients' life after myocardial infarction, is continuously…”
Get full text

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment by Lee, G A, Aktaa, S, Baker, E, Gale, C P, Yaseen, Israa F, Gulati, G, Asteggiano, R, Szmit, S, Cohen-Solal, A, Abdin, A, Jurczak, W, Garrido Lopez, P, Sverdlov, A L, Tocchetti, C G, Barac, A, Parrini, I, Zamorano, P, Iakobishvili, Z, Pudil, R, Badimon, L, Kirby, A M, Blaes, A H, Farmakis, D, Curigliano, G, Stephens, R, Lyon, A R, Lopez-Fernandez, T

“…Abstract Aims To develop quality indicators (QIs) for the evaluation of the prevention and management of cancer therapy-related cardiovascular toxicity…”
Get full text

A phase Ib and randomised phase II trial of pazopanib with or without fosbretabulin in advanced recurrent ovarian cancer by Morgan, R.D., Jayson, G.C., Banerjee, S., Clamp, A.R., Lyon, A.R., Ryder, W.D., Hutson, R., Mescallado, N., Orbegoso Aguilar, C., Taylor, S., Tugwood, J., Hall, M., Dive, C., Rustin, G.J.S.

Get full text

Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens by TITELER, M, LYON, R. A, GLENNON, R. A

“…Alterations in brain serotonergic function have been implicated in the mechanism of action of LSD, mescaline, and other similarly acting hallucinogenic drugs…”
Get full text

Peri-operative cardiac arrest with ST elevation secondary to gelofusin anaphylaxis — Kounis syndrome in the anaesthetic room by Shah, G, Scadding, G, Nguyen-Lu, N, Wigmore, T, Chenzbraun, A, Wechalekar, K, Sharma, R, Lyon, A.R

Get full text

Fidelity-consistency and deliberateness of modifications in parenting programs by Pettersson, Kristoffer, Liedgren, Pernilla, Lyon, Aaron R, Hasson, Henna, von Thiele Schwarz, Ulrica

“…Evidence-based interventions (EBIs) are frequently modified in practice. It is recommended that decisions to modify EBIs should be made deliberately to ensure…”
Get full text

Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology (vol 22, pg 1315, 2020) by Chioncel, O, Parissis, J, Mebazaa, A, Thiele, H, Desch, S, Bauersachs, J, Harjola, VP, Antohi, EL, Arrigo, M, Gal, TB, Celutkiene, J, Collins, SP, DeBacker, D, Iliescu, VA, Jankowska, E, Jaarsma, T, Keramida, K, Lainscak, M, Lund, LH, Lyon, AR, Masip, J, Metra, M, Miro, O, Mortara, A, Mueller, C, Mullens, W, Nikolaou, M, Piepoli, M, Price, S, Rosano, G, Vieillard-Baron, A, Weinstein, JM, Anker, SD, Filippatos, G, Ruschitzka, F, Coats, AJS, Seferovic, P

Get full text

NAN-190: an arylpiperazine analog that antagonizes the stimulus effects of the 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) by Glennon, R A, Naiman, N A, Pierson, M E, Titeler, M, Lyon, R A, Weisberg, E

Get more information

A role for histamine and H2-receptors in opioid antinociception by Gogas, K R, Hough, L B, Eberle, N B, Lyon, R A, Glick, S D, Ward, S J, Young, R C, Parsons, M E

“…To investigate the role of brain H2-receptors in opioid antinociceptive mechanisms, the effects of several antagonists of histamine H2-receptors were…”
Get more information